Amersham gets US approval for Myoview
This article was originally published in Clinica
Executive Summary
Amersham plans to launch its heart imaging agent, Myoview, in the US in March. Recent FDA approval gives Amersham access to the largest market for cardiology imaging. The North American market accounts for £140 million ($213 million) of a £250 million world market. The Tc-99m tetrafosmin kit will be distributed through Medi-Physics, the company's wholly-owned US subsidiary which owns 120 radiopharmacies.